Targeted Oncology Staff

During a live event, Hagen Kennecke, MD, discussed key trials shaping the treatment landscape of PNETs.

Experts explain how MRI trends, seizures, and spectroscopy guide when IDH-mutant glioma monitoring ends and radiation or chemo begins.

FDA oncology updates in February 2026 deliver new approvals, oral and monthly dosing options, and key NDA reviews, easing treatment burden across hard-to-treat cancers.

ASCO GU 2026 previews and FDA rulings spotlight new targeted options in bladder, lung, breast, and colorectal cancers.

During a live event, Shaji Kumar, MD, discussed when talquetamab can be sequenced in multiple myeloma as an alternative to targeting BCMA in consecutive lines.

During a live event, Joshua Richter, MD, discussed dosing strategies when using selinexor in relapsed/refractory multiple myeloma.

Explore frontline chemo‑immunotherapy choices in extensive-stage SCLC, NCCN updates, and why patient drop-off shapes second- and third-line care.

BCMA bispecific teclistamab delivers 63% responses and durable remissions in heavily pretreated myeloma, with new infection prophylaxis insights.

During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.

Explore this week’s oncology breakthroughs: genomic-driven lung cancer care, record survival gains, and FDA moves in myeloma and subcutaneous amivantamab.

During a Case-Based Roundtable event, Timothy Cloughesy, MD, and participants discuss targeted IDH inhibition in patients with grade 2 gliomas.

During a live event, Marc J. Braunstein, MD, PhD, and participants discussed how recent trial findings are affecting their treatment of newly diagnosed multiple myeloma.

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and PRRT.

Maintaining a hematocrit below 45% is the objective in treating patients with low-risk polycythemia vera. Mojtaba Akhtari, MD, and participants explore therapeutic approaches.

During a live event, Edward Pearson, MD, and participants discussed their approaches to using JAK inhibitors in myelofibrosis based on blood cell counts.

FDA moves new breast and colorectal cancer therapies forward, while experts spotlight pancreatic precision drugs and belzutifan safety in ccRCC.

Experts debate MMR/p53 testing, liquid biopsy, and immunotherapy sequencing in endometrial cancer, refining prognosis and relapse treatment.

During a live event, Andrew H. Lipsky, MD, and participants weigh acalabrutinib, zanubrutinib and pirtobrutinib, comparing real-world side effects, cardiac risks, and dosing tradeoffs.

During a virtual event, Aditya Bardia, MD, MPH and participants weigh elacestrant and imlunestrant, comparing real-world adverse effects and efficacy.

During a live event, Sumanta K. Pal and other oncologists discuss the safety and efficacy of belzutifan for advanced renal cell carcinoma, highlighting management of anemia and hypoxia.

Discover the latest FDA approvals and groundbreaking trial results in cancer treatments, including myeloma, pancreatic cancer, and melanoma advancements.

Precision medicine revolutionizes endometrial cancer treatment, emphasizing molecular drivers and the challenges of next-generation sequencing in clinical decision-making.

Experts discuss second-line treatment strategies for clear cell renal cell carcinoma, focusing on efficacy, tolerability, and the role of tivozanib.

Discover the latest breakthroughs in oncology, including FDA approvals and promising trial results for advanced breast cancer and metastatic colorectal cancer.

During a live event, Andrew H. Lipsky, MD, and participants discuss emerging trial data and real-world applications of innovative CLL treatment combinations.

Discover the latest breakthroughs in oncology, including advancements in lung cancer treatments and FDA updates on promising therapies.

During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating lymphocytes in patients with melanoma.